The Expression and Survival Significance of Glucose Transporter-1 in Pancreatic Cancer: Meta-Analysis, Bioinformatics Analysis and Retrospective Study

References

• McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–4861.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43(2):173–180.
   PubMed Web of Science ®Google Scholar
• Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012;24(6):650–654.
   PubMed Web of Science ®Google Scholar
• Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654–662.
   PubMed Web of Science ®Google Scholar
• Frolova AI, Moley KH. Glucose transporters in the uterus: an analysis of tissue distribution and proposed physiological roles. Reproduction. 2011;142(2):211–220.
   PubMed Web of Science ®Google Scholar
• Luo XM, Zhou SH, Fan J. Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res. 2010;38(6):1885–1892.
   PubMed Web of Science ®Google Scholar
• Amann T, Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets. 2009;13(12):1411–1427.
   PubMed Web of Science ®Google Scholar
• Basturk O, Singh R, Kaygusuz E, Balci S, Dursun N, Culhaci N, et al. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas. 2011;40(2):187–192.
   PubMed Web of Science ®Google Scholar
• Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001;37(2):204–209.
   PubMed Web of Science ®Google Scholar
• Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A, et al. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem. 2012;113(2):553–562.
   PubMed Web of Science ®Google Scholar
• Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 2012;37(2):121–127.
   PubMed Web of Science ®Google Scholar
• Cortese N, Capretti G, Barbagallo M, Rigamonti A, Takis PG, Castino GF, et al. metabolome of pancreatic juice delineates distinct clinical profiles of pancreatic cancer and reveals a link between glucose metabolism and PD-1+ cells. Cancer Immunol Res. 2020;8(4):493–505.
   PubMed Web of Science ®Google Scholar
• Hexige S, Ardito-Abraham CM, Wu Y, Wei Y, Fang Y, Han X, et al. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. J Pathol. 2015;236(2):142–154.
   PubMed Web of Science ®Google Scholar
• Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res. 2002;35(1):9–26.
   PubMed Web of Science ®Google Scholar
• Augustin R. The protein family of glucose transport facilitators: it's not only about glucose after all. IUBMB Life. 2010;62(5):315–333.
   PubMed Web of Science ®Google Scholar
• Yu M, Zhou Q, Zhou Y, Fu Z, Tan L, Ye X, et al. Metabolic phenotypes in pancreatic cancer. PLOS One. 2015;10(2):e0115153.
   PubMed Web of Science ®Google Scholar
• Kitasato Y, Yasunaga M, Okuda K, Kinoshita H, Tanaka H, Okabe Y, et al. Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas. Pancreas. 2014;43(7):1060–1065.
   PubMed Web of Science ®Google Scholar
• Pizzi S, Porzionato A, Pasquali C, Guidolin D, Sperti C, Fogar P, et al. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol. 2009;24(2):175–185.
   PubMed Web of Science ®Google Scholar
• Lyshchik A, Higashi T, Hara T, Nakamoto Y, Fujimoto K, Doi R, et al. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 2007;25(3):154–162.
   PubMed Web of Science ®Google Scholar
• Commander R, Wei C, Sharma A, Mouw JK, Burton LJ, Summerbell E, et al. Subpopulation targeting of pyruvate dehydrogenase and GLUT1 decouples metabolic heterogeneity during collective cancer cell invasion. Nat Commun. 2020;11(1):1533.
   PubMed Web of Science ®Google Scholar
• Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55(88):2016–2027.
   PubMedGoogle Scholar
• Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLOS One. 2012;7(2):e31507.
   PubMed Web of Science ®Google Scholar
• Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, et al. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer. 2016;16:632.
   PubMed Web of Science ®Google Scholar
• Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009;16(3):259–266.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102.
   PubMed Web of Science ®Google Scholar
• Sung J-Y, Kim GY, Lim S-J, Park Y-K, Kim YW. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract. 2010; 206(1) :24–29. doi:https://doi.org/10.1016/j.prp.2009.07.018.
   PubMed Web of Science ®Google Scholar
• Lu K, Yang J, Li D-C, He S-B, Zhu D-M, Zhang L-F, et al. Expression and clinical significance of glucose transporter-1 in pancreatic cancer. Oncol Lett. 2016;12(1):243–249.
   PubMed Web of Science ®Google Scholar
• Chikamoto A, Inoue R, Komohara Y, Sakamaki K, Hashimoto D, Shiraishi S, et al. Preoperative high maximum standardized uptake value in association with glucose transporter 1 predicts poor prognosis in pancreatic cancer. Ann Surg Oncol. 2017;24(7):2040–2046.
   PubMed Web of Science ®Google Scholar
• Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, et al. Significance of glucose transporter type 1 (glut-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;25(5):1432–1439.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Nojima H, Kuboki S, Horikoshi T, Yokota T, Yoshitomi H, et al. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer. Pancreatology. 2020;20(6):1205–1212.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801):249–257.
   PubMed Web of Science ®Google Scholar
• Gu J, Saiyin H, Fu D, Li J. Stroma – a double-edged sword in pancreatic cancer: a lesson from targeting stroma in pancreatic cancer with hedgehog signaling inhibitors. Pancreas. 2018;47(4):382–389.
   PubMed Web of Science ®Google Scholar
• Serrano OK, Chaudhry MA, Leach SD. The role of PET scanning in pancreatic cancer. Adv Surg. 2010; 44 :313–325.
   PubMedGoogle Scholar
• Orlando LA, Kulasingam SL, Matchar DB. Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther. 2004;20(10):1063–1070.
   PubMed Web of Science ®Google Scholar
• Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(5 Suppl):1s–93s.
   PubMed Web of Science ®Google Scholar
• Fröhlich A, Diederichs CG, Staib L, Vogel G, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med. 1999;40(2):250–255.
   PubMed Web of Science ®Google Scholar
• Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg. 2004;11(1):4–10.
   PubMedGoogle Scholar
• Sharen G, Peng Y, Cheng H, Liu Y, Shi Y, Zhao J, et al. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget. 2017;8(12):19760–19767.
   PubMedGoogle Scholar